Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from December 10, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on March 10, 2026.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$46.00 – $48.00Entry zone — fair-value band

$47.64Published — price the day we called it

$57.17Target — the price the thesis aimed for

$64.16Peak — highest point inside the window, not a realized return

$38.72Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 27 days.

Peak price

$64.16

peak on January 23, 2026 — not a realized return

Peak gain

+34.7%

peak, from the publication price

Window close

$38.72

end-of-window price, context only

Days to target

Window

December 10, 2025 – March 10, 2026

The thesis — published December 10, 2025

Predicted growth

+20%

over the measurement window

Target price

$57.17

the price the thesis aimed for

Entry zone

$46.00 – $48.00

the fair-value band we waited for

Price at publication

$47.64

published December 10, 2025

Confidence

70%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk is a major healthcare company that sells medicines for diabetes and obesity. After a large drop, a valuation review suggests the stock may be much cheaper than fundamentals imply. Recent trading shows many more buyers than usual around the mid-$40s, and steady demand for GLP-1 drugs could lift the stock in the next few months despite policy and valuation risks.

Primary drivers

World leader in GLP-1 drugs for diabetes and obesity, driving sales growth.
Valuation work on Dec 10 suggests the stock could be cheaper than its true value.
Recent trading shows many more people buying than usual after the selloff.
Ongoing demand for obesity treatments supports steady revenue prospects despite pricing risk.

How it played out

NVO: target reached in 27 days

On Dec. 10, Lyra published a short-term NVO thesis at $47.64. It expected 20% growth toward $57.17. The thesis pointed to Novo Nordisk's GLP-1 position in diabetes and obesity, a valuation review after the drop, heavier buying around the mid-$40s, and continued demand for obesity treatments despite policy and valuation risks.

Inside the window, NVO reached the target in 27 days. It peaked at $64.16 on Jan. 23, with a peak gain of 34.7%. The stock then gave back that move and ended at $38.72 on Mar. 10. The thesis played out on target timing, but not by the window close.

What happened during the window

On Jan. 5, 2026, The Guardian reported that Novo Nordisk launched a Wegovy weight-loss pill in the U.S. On Feb. 3, 2026, Novo Nordisk reported financial results for 2025, according to its financial report listing cited in public company references.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals